Phase 3 Clinical Trials With Primary Completion Dates in July 2020
This is a list of Phase 3 trials with primary completion dates in July 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AMAG | AMAG Pharmaceuticals, Inc. | 2020-07-01 | Phase 3 | NCT03893045 | A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects |
| AMPE | Ampio Pharmaceuticals, Inc. | 2020-07-01 | Phase 3 | NCT03988023 | Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee. |
| AXSM | Axsome Therapeutics, Inc. | 2020-07-01 | Phase 3 | NCT04039022 | Open-Label Safety Study of AXS-05 in Subjects With Depression |
| EXEL | Exelixis, Inc. | 2020-07-01 | Phase 3 | NCT03690388 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy |
| MCRB | Seres Therapeutics, Inc. | 2020-07-01 | Phase 3 | NCT03183128 | ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection |
| MEDP | Medpace Holdings, Inc. | 2020-07-01 | Phase 3 | NCT03464019 | Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301 |
| MIST | Milestone Pharmaceuticals Inc. | 2020-07-01 | Phase 3 | NCT03464019 | Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301 |
| MYL | Mylan N.V. | 2020-07-01 | Phase 3 | NCT04344041 | COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial) |
| NKTR | Nektar Therapeutics | 2020-07-01 | Phase 3 | NCT02915744 | A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine |
| OCGN | Ocugen, Inc. | 2020-07-01 | Phase 3 | NCT03591874 | Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease |
| ONPH | Oncology Pharma Inc. | 2020-07-01 | Phase 3 | NCT02819960 | Prevention of Irinotecan Induced Diarrhea by Probiotics |
| OTLK | Outlook Therapeutics, Inc. | 2020-07-01 | Phase 3 | NCT03844074 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) |
| RTRX | Retrophin, Inc. | 2020-07-01 | Phase 3 | NCT03041116 | Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Patients |
| VNDA | Vanda Pharmaceuticals Inc. | 2020-07-01 | Phase 3 | NCT04028492 | Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis |
| VSTM | Verastem, Inc. | 2020-07-01 | Phase 3 | NCT02049515 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 |
| ZGNX | Zogenix, Inc. | 2020-07-01 | Phase 3 | NCT02826863 | A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome |
| ZGNX | Zogenix, Inc. | 2020-07-01 | Phase 3 | NCT02682927 | A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome |